Table 1.
Clinical Characteristics of the Study Population.
| Characteristic | CK19 negative (151) | CK19 positive (106) | p-value |
|---|---|---|---|
| Age | 0.266 | ||
| ≥50 | 112 | 71 | |
| <50 | 39 | 35 | |
| Gender | 0.009 | ||
| Male | 141 | 87 | |
| Female | 10 | 19 | |
| Differentiation | 0.719 | ||
| Good | 63 | 41 | |
| Poor | 88 | 65 | |
| Tumor size | 0.600 | ||
| ≥5 cm | 66 | 42 | |
| <5 cm | 85 | 64 | |
| Tumor number | 0.711 | ||
| Single | 93 | 62 | |
| Multiple | 58 | 44 | |
| Microvascular invasion | 0.089 | ||
| Yes | 54 | 50 | |
| No | 97 | 56 | |
| Macrovascular invasion | 0.581 | ||
| Yes | 18 | 16 | |
| No | 133 | 90 | |
| Lymph node metastasis | 0.688 | ||
| Yes | 2 | 3 | |
| No | 149 | 103 | |
| Cirrhosis | 0.651 | ||
| Yes | 106 | 78 | |
| No | 45 | 28 | |
| HBV infection | 0.699 | ||
| Yes | 136 | 93 | |
| No | 15 | 13 | |
| PLT | 135.50 ± 59.40 | 149.10 ± 75.17 | 0.107 |
| ALB | 39.96 ± 5.66 | 40.79 ± 5.97 | 0.255 |
| ALT | 50.58 ± 101.03 | 50.16 ± 63.79 | 0.970 |
| AST | 60.45 ± 158.22 | 55.16 ± 77.12 | 0.750 |
| GGT | 114.74 ± 158.89 | 93.17 ± 85.55 | 0.204 |
| FBG | 5.46 ± 1.68 | 5.76 ± 2.15 | 0.215 |
| TB | 19.60 ± 19.55 | 26.24 ± 50.65 | 0.145 |
| DB | 10.03 ± 16.31 | 15.08 ± 43.95 | 0.198 |
| IB | 9.58 ± 6.69 | 11.19 ± 8.72 | 0.096 |
| Serum AFP | 2,666.07 ± 11,635.29 | 4,312.00 ± 14,029.66 | 0.307 |
| Serum CEA | 3.14 ± 1.77 | 3.37 ± 4.59 | 0.588 |
| Serum CA19-9 | 84.60 ± 840.43 | 19.54 ± 33.05 | 0.427 |
HBV, hepatitis B virus; PLT, platelet; ALB, albumin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma-glutamyl transferase; FBG, fasting blood glucose; TB, total bilirubin; DB, direct bilirubin; IB, indirect bilirubin; AFP, α-fetoprotein; CEA, carcinoembryonic antigen; CA19-9, carbohydrate antigen 19-9.
Bold values indicate statistically different at P values < 0.05.